CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration

被引:200
作者
Loberg, Robert D.
Ying, Chi
Craig, Matt
Yan, Li
Snyder, Linda A.
Pienta, Kenneth J.
机构
[1] Univ Michigan, Urol Ctr, Dept Urol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Centocor Inc, Dept Hematol Oncol, Malvern, PA 19355 USA
来源
NEOPLASIA | 2007年 / 9卷 / 07期
关键词
monocyte chemoattractant protein 1; prostate cancer; chemokine; tumor-associated macrophage; angiogenesis;
D O I
10.1593/neo.07307
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ability of CCL2 to influence prostate cancer tumorigenesis and metastasis may occur through two distinct mechanisms: 1) a direct effect on tumor cell growth and function, and 2) an indirect effect on the tumor microenvironment by the regulation of macrophage mobilization and infiltration into the tumor bed. We have previously demonstrated that CCL2 exerts a direct effect on prostate cancer epithelial cells by the regulation of their growth, invasion, and migration, resulting in enhanced tumorigenesis and metastasis. Here we describe an indirect effect of CCL2 on prostate cancer growth and metastasis by regulating monocyte/ macrophage infiltration into the tumor microenvironment and by stimulating a phenotypic change within these immune cells to promote tumor growth (tumor-associated macrophages). VCaP prostate cancer cells were subcutaneously injected in male SCID mice and monitored for tumor volume, CD68(+) macrophage infiltration, and microvascular density. Systemic administration of antiCCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68(+) macrophage infiltration, which was accompanied by a significant decrease in microvascular density. These data suggest that CCL2 contributes to prostate cancer growth through the regulation of macrophage infiltration and enhanced angiogenesis within the tumor.
引用
收藏
页码:556 / 562
页数:7
相关论文
共 15 条
[1]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[2]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[3]  
Korenchuk S, 2001, IN VIVO, V15, P163
[4]   Monocyte chemoattractant protein-1 serum levels in patients with breast cancer [J].
Lebrecht, A ;
Grimm, C ;
Lantzsch, T ;
Ludwig, E ;
Hefler, L ;
Ulbrich, E ;
Koelbl, H .
TUMOR BIOLOGY, 2004, 25 (1-2) :14-17
[5]   Development of the VCaP androgen-independent model of prostate cancer [J].
Loberg, RD ;
St John, LN ;
Day, LL ;
Neeley, CK ;
Pienta, KJ .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (02) :161-168
[6]  
LOBERG RD, IN PRESS CANCER
[7]   CCL2 is a potent regulator of prostate cancer cell migration and proliferation [J].
Loberg, Robert D. ;
Day, LaShon L. ;
Harwood, Jason ;
Ying, Chi ;
John, Lauren N. St. ;
Giles, Ryan ;
Neeley, Chris K. ;
Pienta, Kenneth J. .
NEOPLASIA, 2006, 8 (07) :578-586
[8]   Inflammation, a key event in cancer development [J].
Lu, HT ;
Ouyang, WM ;
Huang, CS .
MOLECULAR CANCER RESEARCH, 2006, 4 (04) :221-233
[9]   Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption [J].
Lu, Yi ;
Cai, Zhong ;
Xiao, Guozhi ;
Keller, Evan T. ;
Mizokami, Atsushi ;
Yao, Zhi ;
Roodman, G. David ;
Zhang, Jian .
CANCER RESEARCH, 2007, 67 (08) :3646-3653
[10]   Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion [J].
Lu, Yi ;
Cai, Zhong ;
Galson, Deborah L. ;
Xiao, Guozhi ;
Liu, Yulin ;
George, Diane E. ;
Melhem, Mona F. ;
Yao, Zhi ;
Zhang, Jian .
PROSTATE, 2006, 66 (12) :1311-1318